# AviadoBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aviadobio

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.aviadobio.com
- Total disclosed funding: $93M
- Latest round: Series A (Dec 2, 2021)
- Investors on record: 8

## About

Based in London, UK, and founded in 2019 by Chris Shaw, Youn Bok Lee, and Do Young Lee, AviadoBio Limited is a developer of transformative gene therapies for patients with neurodegenerative disorders. In December 2021, AviadoBio Limited raised GBP 58.6 million in series A funding co-led by investors Monograph Capital Partners and New Enterprise Associates, with participation from other investors Advent Life Sciences, Dementia Discovery Fund, EQT Life Sciences, LifeArc, etc. As of January 2024, the company is led by its CEO, Lisa Deschamps.

AviadoBio Limited provides transformative gene therapies for patients with life-threatening neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) through the potential of gene therapy.

## Funding rounds

- Series A, Dec 2, 2021, $78M — New Enterprise Associates, EQT Life Sciences, Johnson & Johnson Innovation, F-Prime Capital, Advent Life Sciences, Dementia Discovery Fund, Monograph Capital, LifeArc
- Seed, Sep 11, 2020, $15M — Johnson & Johnson Innovation, F-Prime Capital, Advent Life Sciences, Dementia Discovery Fund, LifeArc

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Seed, Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Seed, Series A
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Seed, Series A
- Dementia Discovery Fund — Seed, Series A
- LifeArc (https://capitalatlas.ai/funds/lifearc) — Seed, Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- Monograph Capital (https://capitalatlas.ai/funds/monograph-capital) — Series A